Summary

for people ages 18 years and up (full criteria)
at Sacramento, California and other locations
study started
estimated completion
Erik Chak, MD

Description

Summary

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.

Keywords

Hepatitis B Hepatitis Liver Diseases Hepatitis A Hepatitis, Chronic Hepatitis B, Chronic TAF tenofovir alafenamide

Eligibility

For people ages 18 years and up

Inclusion Criteria:

  • Male or female patients, age ≥18 years
  • On a stable antiviral therapy regimen for hepatitis B as determined by treating physician

Exclusion

  • Inability to provide written informed consent/assent
  • Known coinfection with hepatitis Delta
  • Known history of Human Immunodeficiency Virus (HIV)

Locations

  • UC Davis GI/Hepatology Clinical Trials Unit accepting new patients
    Sacramento California 95817 United States
  • Silicon Valley Research Institute accepting new patients
    San Jose California 95128 United States

Lead Scientist

  • Erik Chak, MD
    Assistant Professor, Gastroenterology and Hepatology. Authored (or co-authored) 8 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Target PharmaSolutions, Inc.
Links
Sign up for this study
ID
NCT03692897
Study Type
Observational
Last Updated